Recent Updates
Recently added Catalysts

Dexamethasone nanoparticles eye

Phase 2

Diabetic Macular Edema | Small molecule | Ophthalmology |Oculis Holding AG|Last Updated: Jun 27, 2022

Target and mechanism

ModalitySmall molecule

Also known as Dexamethasone nanoparticles eye drops

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment144

FDA Designations

No designations recorded

Clinical trial landscape

Dexamethasone nanoparticles eye · 1 trial · 1 indication

Phase 2 1
NCT05343156Efficacy and Safety of Dexamethasone Nanoparticles Eye Drops in Diabetic Macular EdemaDiabetic Macular Edema
COMPLETED144 Analytics
PHASE2COMPLETED
Efficacy and Safety of Dexamethasone Nanoparticles Eye Drops in Diabetic Macular Edema
Diabetic Macular Edema
NCT05343156144
Unlock trial analytics

Study Design & Arms

Interventions

NameTypeDescription
Dexamethasone nanoparticles eye dropsDRUGDexNP 15 mg/mL eye drops 3 times a day (every 8 hours) for 12 weeks
Unlock Study Design Details

Competitive Landscape -Diabetic Macular Edema 14 trials

CompanyTickerTrialsLead PhaseDrugs
EyePoint, Inc.EYPT2PHASE3EYP-1901, Aflibercept
Regeneron Pharmaceuticals, Inc.REGN1PHASE3Aflibercept
Oculis Holding AGOCS2PHASE3Dexamethasone, Vehicle
AbbVie, Inc.ABBV2PHASE2ABBV-RGX-314 Dose 1, Steroid, Aflibercept
Outlook Therapeutics, Inc.OTLK1PHASE3bevacizumab
4D Molecular Therapeutics, Inc.FDMT1PHASE24D-150 IVT, Aflibercept IVT
AlvotechALVO1PHASE3AVT29, Eylea HD
Kiora Pharmaceuticals, Inc.KPRX1PHASE2KIO-104
REGENXBIO, Inc.RGNX1PHASE2RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept
Ocugen IncOCGN1PHASE1OCU200
Adverum Biotechnologies, Inc.ADVM1 - ADVM-022
Unlock Competitive Intelligence